{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:00:22Z","timestamp":1792116022005,"version":"4.4.0"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Topical opioid formulations offer a potential solution to manage pain and decrease the use of systemic opioids. Synthesis of use and efficacy of topical opioids in dermatological conditions has not been well characterized. We conducted a systematic search of the PubMed, Embase, and Cochrane databases from 1980 to February 2021. This study analyzed data from 14 articles and 263 patients on the use of topical opioids for pain related to chronic ulcers, burns, oral lichen planus, photodynamic therapy, and split\u2010thickness skin grafts. Topical opioids included in this review were topical morphine and diamorphine. Common formulations consisted of 0.2\u201310\u00a0mg of opioid compounded with hydrogel or IntraSite gel. Topical opioids were variably effective in the use for pain control related to chronic ulcers and other dermatologic conditions. For example, the use of topical opioids appears to be effective in the reduction of pain related to pressure ulcers. Topical opioids were generally well tolerated. Insufficient data exist to adequately evaluate the efficacy and safety of topical opioid use in the context of nonpressure ulcers, burns, oral lichen planus, photodynamic therapy, and split\u2010thickness skin grafts.<\/jats:p>","DOI":"10.1111\/dth.15150","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T20:55:41Z","timestamp":1633380941000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Topical opioid use in dermatologic disease: A systematic review"],"prefix":"10.1155","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-1511","authenticated-orcid":false,"given":"Yasmin","family":"Gutierrez","sequence":"first","affiliation":[{"name":"School of Medicine University of California Riverside  Riverside California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-3145","authenticated-orcid":false,"given":"Sarah P.","family":"Pourali","sequence":"additional","affiliation":[{"name":"School of Medicine Vanderbilt University  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9308-1086","authenticated-orcid":false,"given":"Alison H.","family":"Kucharik","sequence":"additional","affiliation":[{"name":"Charles E. Schmidt College of Medicine Florida Atlantic University  Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-6252","authenticated-orcid":false,"given":"Madison E.","family":"Jones","sequence":"additional","affiliation":[{"name":"Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-7161","authenticated-orcid":false,"given":"Jeffrey R.","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"College of Medicine at Chicago University of Illinois  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.11.038"},{"key":"e_1_2_9_3_1","unstructured":"Center for Disease Control and Prevention National Center for Injury Prevention and Control. Opioids.https:\/\/www.cdc.gov\/drugoverdose\/opioids\/index.html. Last updated 16 March 2021. Accessed March 26 2021."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1414551"},{"key":"e_1_2_9_5_1","unstructured":"Actavis Pharma. Drug Approval Package Label: EMLA Cream. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/019941s021lbl.pdf. Revised November 2018. Accessed December 14 2020."},{"key":"e_1_2_9_6_1","unstructured":"Novartis Pharma Produktions GmbH. Drug Approval Package Label: Voltaren Gel. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022122s010lbl.pdf. Revised May 2016. Accessed December 14 2020."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182459abd"},{"key":"e_1_2_9_8_1","unstructured":"Almirall Hermal GmbH. Drug Approval Package Label: Solaraze Gel. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021005s013lbl.pdf. Revised December 2011. Accessed December 14 2020."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aer260"},{"key":"e_1_2_9_10_1","unstructured":"Lohmann Therapie\u2010Systeme AG (L TS). Drug Approval Package Label: Qutenza. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022395lbl.pdf. Revised November 2009. Accessed December 14 2020."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-00923-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-019-00739-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2011.02271.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00844.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00123"},{"key":"e_1_2_9_16_1","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). Topical Morphine for Analgesia in Patients With Skin Grafts. Identifier: NCT00362219.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00362219. Last updated 11 March 2021. Accessed March 26 2021."},{"key":"e_1_2_9_17_1","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). Use of Morphine Gel Topically in Patients With Stage 2\u20133 Wounds. Identifier: NCT00755989.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00755989?term=topical+opioid&amp;draw=7&amp;rank=49. Last updated 19 September 2008. Accessed March 26 2021."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-200103000-00006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2007.047324"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-017-2112-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0128"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijso.2016.05.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2011.01252.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_26_1","first-page":"E37","article-title":"Morphine versus Loperamide with Intrasite gel in the treatment of painful dermal ulcers: a randomized, crossover study","volume":"24","author":"Jyothi B","year":"2021","journal-title":"Pain Physician"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2011.00901.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-011-2141-x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2009.18.7.43115"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.08.011"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2005.14.6.26793"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.10.002"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00140-4"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00146-5"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_9_37_1","unstructured":"The Ottawa Hospital Research Institute. Newcastle \u2010 Ottawa Quality Assessment Scale.http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nosgen.pdf. Accessed November 12 2021."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.12.006"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216305pm985oa"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.08.016"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2005.01142.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9328"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2017.06.010"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15344"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000001615"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.1.1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322506"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.15150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:10:14Z","timestamp":1713946214000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.15150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/dth.15150"],"URL":"https:\/\/doi.org\/10.1111\/dth.15150","archive":["Portico"],"relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"value":"1396-0296","type":"print"},{"value":"1529-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"2021-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15150"}}